Dr. Abdullah M. S. Al-Osaimi is an Assistant Professor of Medicine and Surgery and the Associate Medical Director of Liver Transplantation in the Division of Gastroenterology and Hepatology, at the University of Virginia. He graduated with an M.B.B.S. from the University of King Saud in Riyadh, Saudi Arabia.  Dr. Al-Osaimi completed his Medicine Residency and Gastroenterology and Hepatology Fellowship training at the King Faisal Specialist Hospital and Research Centre in Riyadh Saudi Arabia.  He then joined UVA for a fourth year fellowship of advanced Hepatology and Liver Transplantation, which was extended for a fifth year, to complete his required documents to transition to a UVA liver faculty position.  Dr. Al-Osaimi joined the faculty at UVA in 2003 as a Clinical Instructor of Medicine and in 2004 was prompted to assistant professor of medicine. Dr. Al-Osaimi’s clinical practice focuses on the diagnosis and management of liver disorders with emphasis on non-alcoholic fatty liver disease (NAFLD/NASH) and liver transplantation in addition to ultra-sound guided liver biopsies.  Dr. Al-Osaimi has been recognized and recently funded by the NIH for the development of a novel magnetic resonance spectroscopy imaging in assessing liver fibrosis in patients with NAFLD and NASH.  He is a principle investigator for multiple pharma-sponsored protocols in the treatment of chronic hepatitis C in the pre-transplant and non-transplant settings in addition to novel therapies for hepatic fibrosis.  Dr. Al-Osaimi is an active member of the AASLD and serves on the AASLD annual education committee and a DDW abstract reviewer for multiple sub-committees in addition to a referee for more than 16 national and international scientific journals.

Dr. Al-Osaimi's research interests focus on developing novel non-invasive approaches to assess liver fibrosis, as well as novel approaches to living donor liver transplantation, with special interest in recurrent viral hepatitis.  He is currently studying Non-alcoholic Fatty Liver Disease epidemiology in high risk groups, pathogenesis and different modalities of therapy. Dr. Al-Osaimi has developed (with Dr. Caldwell) a multidisciplinary Hepatocellular Carcinoma Tumor Board dedicated to novel approaches and modalities of therapy for Hepatocellular Carcinoma.  Dr. Al-Osaimi is involved in multiple sponsored trials in Viral Hepatitis C, Non-alcoholic Fatty Liver Disease and Platelet Growth Factors for patient with Thrombocytopenia.